Siegel R.L. Miller K.D. Fuchs H.E. et al.

Cancer statistics.

CA Cancer J Clin. 72: 7-33

Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969-2019). National Cancer Institute, DCCPS.

()

Extent of surgery for papillary thyroid carcinoma: the debate continues: comment on "surgery for papillary thyroid carcinoma.

Arch Otolaryngol Head Neck Surg. 136: 1061-1063Perrier N.D. Brierley J.D. Tuttle R.M.

Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

CA Cancer J Clin. 68: 55-63Tam S. Boonsripitayanon M. Amit M. et al.

Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions.

Thyroid. 28: 1301-1310Lang B.H. Lo C.Y. Chan W.F. et al.

Staging systems for papillary thyroid carcinoma: a review and comparison.

Ann Surg Mar. 245: 366-378Dwamena S. Patel N. Egan R. et al.

Impact of the change from the seventh to eighth edition of the AJCC TNM classification of malignant tumours and comparison with the MACIS prognostic scoring system in non-medullary thyroid cancer.

BJS Open. 3: 623-628Hay I.D. Grant C.S. Taylor W.F. et al.

Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system.

Surgery. 102: 1088-1095

An expanded view of risk-group definition in differentiated thyroid carcinoma.

Surgery. 104: 947-953Hay I.D. Bergstralh E.J. Goellner J.R. et al.

Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989.

Surgery. 114 (): 1050-1057Shah J.P. Loree T.R. Dharker D. et al.

Lobectomy versus total thyroidectomy for differentiated carcinoma of the thyroid: a matched-pair analysis.

Am J Surg. 166: 331-335Hay I.D. Grant C.S. Bergstralh E.J. et al.

Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma?.

Surgery. 124 (): 958-964Bilimoria K.Y. Bentrem D.J. Ko C.Y. et al.

Extent of surgery affects survival for papillary thyroid cancer.

Ann Surg. 246 (): 375-381David S. Cooper G.M.D. Haugen Bryan R. Kloos Richard T. et al.

Tuttle. Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer.

Thyroid. 19: 1167-1214Barney B.M. Hitchcock Y.J. Sharma P. et al.

Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer.

Head Neck. 33: 645-649Mendelsohn A.H. Elashoff D.A. Abemayor E. et al.

Surgery for papillary thyroid carcinoma: is lobectomy enough?.

Arch Otolaryngol Head Neck Surg. 136: 1055-1061Nixon I.J. Ganly I. Patel S.G. et al.

Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy.

Surgery. 151: 571-579Adam M.A. Pura J. Gu L. et al.

Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients.

Ann Surg. 260 (): 601-605Adam M.A. Pura J. Goffredo P. et al.

Impact of extent of surgery on survival for papillary thyroid cancer patients younger than 45 years.

J Clin Endocrinol Metab. 100: 115-121Haugen B.R. Alexander E.K. Bible K.C. et al.

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Thyroid : official J Am Thyroid Assoc. 26: 1-133Tufano R.P. Teixeira G.V. Bishop J. et al.

BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.

Medicine (Baltimore). 91: 274-286Xing M. Alzahrani A.S. Carson K.A. et al.

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.

Jama. 309: 1493-1501Chen Y. Sadow P.M. Suh H. et al.

BRAF(V600E) Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta-Analysis.

Thyroid. 26: 248-255Niederer-Wüst S.M. Jochum W. Förbs D. et al.

Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer.

Surgery. 157: 119-125Melo M. da Rocha A.G. Vinagre J. et al.

TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.

J Clin Endocrinol Metab. 99: E754-E765Xing M. Liu R. Liu X. et al.

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.

J Clin Oncol. 32: 2718-2726Alexander E.K. Kennedy G.C. Baloch Z.W. et al.

Preoperative diagnosis of benign thyroid nodules with indeterminate cytology.

N Engl J Med. 367: 705-715Nikiforov Y.E. Carty S.E. Chiosea S.I. et al.

Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology.

Thyroid. 25: 1217-1223Livhits M.J. Zhu C.Y. Kuo E.J. et al.

Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid Nodules: A Randomized Clinical Trial.

JAMA Oncol. 7: 70-77Ito Y. Uruno T. Nakano K. et al.

An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid.

Thyroid. 13: 381-387Ito Y. Miyauchi A. Inoue H. et al.

An observational trial for papillary thyroid microcarcinoma in Japanese patients.

World J Surg. 34: 28-35Brito J.P. Ito Y. Miyauchi A. et al.

A Clinical Framework to Facilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarcinoma.

Thyroid. 26: 144-149Applewhite M.K. James B.C. Kaplan S.P. et al.

Quality of Life in Thyroid Cancer is Similar to That of Other Cancers with Worse Survival.

World J Surg. 40: 551-561Mongelli M.N. Giri S. Peipert B.J. et al.

Financial burden and quality of life among thyroid cancer survivors.

Surgery. 167: 631-637Sawka A.M. Ghai S. Rotstein L. et al.

A Quantitative Analysis Examining Patients' Choice of Active Surveillance or Surgery for Managing Low-Risk Papillary Thyroid Cancer.

Thyroid. https://doi.org/10.1089/thy.2021.0485Noguchi S. Noguchi A. Murakami N.

Papillary carcinoma of the thyroid. II. Value of prophylactic lymph node excision.

Cancer. 26: 1061-1064Kouvaraki M.A. Shapiro S.E. Fornage B.D. et al.

Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer.

Surgery. 134: 946-954Popadich A. Levin O. Lee J.C. et al.

A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer.

Surgery. 150: 1048-1057Hughes D.T. Rosen J.E. Evans D.B. et al.

Prophylactic Central Compartment Neck Dissection in Papillary Thyroid Cancer and Effect on Locoregional Recurrence.

Ann Surg Oncol. 25: 2526-2534Wang T.S. Cheung K. Farrokhyar F. et al.

A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rates in patients with papillary thyroid cancer.

Ann Surg Oncol. 20: 3477-3483Tuttle M. Morris L. Haugen B. et al.

Thyroid-differentiated and anaplastic carcinoma (Chapter 73).

Springer International Publishing, Nixon I.J. Wang L.Y. Palmer F.L. et al.

The impact of nodal status on outcome in older patients with papillary thyroid cancer.

Surgery. 156: 137-146Shen W.T. Ogawa L. Ruan D. et al.

Central neck lymph node dissection for papillary thyroid cancer: the reliability of surgeon judgment in predicting which patients will benefit.

Surgery. 148: 398-403Lee D.Y. Oh K.H. Cho J.G. et al.

The Benefits and Risks of Prophylactic Central Neck Dissection for Papillary Thyroid Carcinoma: Prospective Cohort Study.

Int J Endocrinol. 2015: 571480Viola D. Materazzi G. Valerio L. et al.

Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study.

J Clin Endocrinol Metab. 100: 1316-1324Kim B.Y. Choi N. Kim S.W. et al.

Randomized trial of prophylactic ipsilateral central lymph node dissection in patients with clinically node negative papillary thyroid microcarcinoma.

Eur Arch Otorhinolaryngol. 277: 569-576Sippel R.S. Robbins S.E. Poehls J.L. et al.

A Randomized Controlled Clinical Trial: No Clear Benefit to Prophylactic Central Neck Dissection in Patients With Clinically Node Negative Papillary Thyroid Cancer.

Ann Surg. 272: 496-503Ahn J.H. Kwak J.H. Yoon S.G. et al.

A prospective randomized controlled trial to assess the efficacy and safety of prophylactic central compartment lymph node dissection in papillary thyroid carcinoma.

Surgery. 171: 182-189Sanabria A. Betancourt C. Sanchez J.G. et al.

Prophylactic Central Neck Lymph Node Dissection in Low-Risk Thyroid Carcinoma Patients Does not Decrease the Incidence of Locoregional Recurrence: A Meta-Analysis of Randomized Trials.

Ann Surg. https://doi.org/10.1097/SLA.0000000000005388Song E. Han M. Oh H.S. et al.

Lobectomy Is Feasible for 1-4 cm Papillary Thyroid Carcinomas: A 10-Year Propensity Score Matched-Pair Analysis on Recurrence.

Thyroid. 29: 64-70Wilhelm S.M. Wang T.S. Ruan D.T. et al.

The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism.

JAMA Surg. 151: 959-968Kebebew E. Hwang J. Reiff E. et al.

Predictors of single-gland vs multigland parathyroid disease in primary hyperparathyroidism: a simple and accurate scoring model.

Arch Surg. 141 (): 777-782Broome D.T. Naples R. Bailey R. et al.

Use of Preoperative Imaging in Primary Hyperparathyroidism.

J Clin Endocrinol Metab. 106: e328-e337Cheung K. Wang T.S. Farrokhyar F. et al.

A meta-analysis of preoperative localization techniques for patients with primary hyperparathyroidism.

Ann Surg Oncol. 19: 577-583Vu T.H. Schellingerhout D. Guha-Thakurta N. et al.

Solitary Parathyroid Adenoma Localization in Technetium Tc99m Sestamibi SPECT and Multiphase Multidetector 4D CT.

AJNR Am J Neuroradiol. 40: 142-149Kuo L.E. Bird S.H. Lubitz C.C. et al.

Four-dimensional computed tomography (4D-CT) for preoperative parathyroid localization: A good study but are we using it?.

Am J Surg. 223: 694-698Abbott D.E. Cantor S.B. Grubbs E.G. et al.

Outcomes and economic analysis of routine preoperative 4-dimensional CT for surgical intervention in de novo primary hyperparathyroidism: does clinical benefit justify the cost?.

J Am Coll Surg. 214 (): 629-637Lubitz C.C. Stephen A.E. Hodin R.A. et al.

Preoperative localization strategies for primary hyperparathyroidism: an economic analysis.

Ann Surg Oncol. 19: 4202-4209Wang T.S. Cheung K. Farrokhyar F. et al.

Would scan, but which scan? A cost-utility analysis to optimize preoperative imaging for primary hyperparathyroidism.

Surgery. 150: 1286-1294Graves C.E. Hope T.A. Kim J. et al.

Superior sensitivity of (18)F-fluorocholine: PET localization in primary hyperparathyroidism.

Surgery. 171: 47-54Latge A. Riehm S. Vix M. et al.

(18)F-Fluorocholine PET and 4D-CT in Patients with Persistent and Recurrent Primary Hyperparathyroidism.

Diagnostics (Basel). 11Chiu B. Sturgeon C. Angelos P.

Which intraoperative parathyroid hormone assay criterion best predicts operative success? A study of 352 consecutive patients.

Arch Surg May. 141 (): 483-487Di Marco A. Mechera R. Glover A. et al.

Focused parathyroidectomy without intraoperative parathyroid hormone measurement in primary hyperparathyroidism: Still a valid approach?.

Surgery. 170: 1383-1388McWade M.A. Paras C. White L.M. et al.

A novel optical approach to intraoperative detection of parathyroid glands.

Surgery. 154 (): 1371-1377McWade M.A. Sanders M.E. Broome J.T. et al.

Establishing the clinical utility of autofluorescence spectroscopy for parathyroid detection.

Surgery. 159: 193-202Akbulut S. Erten O. Kim Y.S. et al.

Development of an algorithm for intraoperative autofluorescence assessment of parathyroid glands in primary hyperparathyroidism using artificial intelligence.

Surgery. 170: 454-461Squires M.H. Jarvis R. Shirley L.A. et al.

Intraoperative Parathyroid Autofluorescence Detection in Patients with Primary Hyperparathyroidism.

Ann Surg Oncol. 26: 1142-1148Kim D.H. Kim S.W. Kang P. et al.

Near-Infrared Autofluorescence Imaging May Reduce Temporary Hypoparathyroidism in Patients Undergoing Total Thyroidectomy and Central Neck Dissection.

Thyroid. 31: 1400-1408Cetani F. Pardi E. Marcocci C.

Parathyroid Carcinoma.

Front Horm Res. 51: 63-76Silva-Figueroa A.M. Hess K.R. Williams M.D. et al.

Prognostic Scoring System to Risk Stratify Parathyroid Carcinoma.

J Am Coll Surg. https://doi.org/10.1016/j.jamcollsurg.2017.01.060Asare E.A. Silva-Figueroa A. Hess K.R. et al.

Risk of Distant Metastasis in Parathyroid Carcinoma and Its Effect on Survival: A Retrospective Review from a High-Volume Center.

Ann Surg Oncol. 26: 3593-3599https://doi.org/10.1245/s10434-019-07451-3Hsu K.T. Sippel R.S. Chen H. et al.

Is central lymph node dissection necessary for parathyroid carcinoma?.

Surgery. 156 (): 1336-1341https://doi.org/10.1016/j.surg.2014.08.005Salcuni A.S. Cetani F. Guarnieri V. et al.

Parathyroid carcinoma.

Best Pract Res Clin Endocrinol Metab. 32: 877-889https://doi.org/10.1016/j.beem.2018.11.002Kutahyalioglu M. Nguyen H.T. Kwatampora L. et al.

Genetic profiling as a clinical tool in advanced parathyroid carcinoma.

J Cancer Res Clin Oncol. 145: 1977-1986https://doi.org/10.1007/s00432-019-02945-9Kang H. Pettinga D. Schubert A.D. et al.

Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.

Oncologist. 24: 791-797Silva-Figueroa A. Villalobos P. Williams M.D. et al.

Characterizing parathyroid carcinomas and atypical neoplasms based on the expression of programmed death-ligand 1 expression and the presence of tumor-infiltrating lymphocytes and macrophages.

Surg Nov. 164: 960-964Park D. Airi R. Sherman M.

Microsatellite instability driven metastatic parathyroid carcinoma managed with the anti-PD1 immunotherapy, pembrolizumab.

BMJ Case Rep. : 13https://doi.org/10.1136/bcr-2020-235293Lenschow C. Fuss C.T. Kircher S. et al.

Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management.

Front Endocrinol (Lausanne). 12: 643328Kebebew E. Siperstein A.E. Duh Q.Y.

Laparoscopic adrenalectomy: the optimal surgical approach.

J Laparoendosc Adv Surg Tech A. 11: 409-413https://doi.org/10.1089/10926420152761941Lee J. El-Tamer M. Schifftner T. et al.

Open and laparoscopic adrenalectomy: analysis of the National Surgical Quality Improvement Program.

J Am Coll Surg. 206 (): 953-959Elfenbein D.M. Scarborough J.E. Speicher P.J. et al.

Comparison of laparoscopic versus open adrenalectomy: results from American College of Surgeons-National Surgery Quality Improvement Project.

J Surg Res. 184: 216-220Romero Arenas M.A. Sui D. Grubbs E.G. et al.

Adrenal metastectomy is safe in selected patients.

World J Surg. 38: 1336-1342Lindeman B. Gawande A.A. Moore Jr., F.D. et al.

The Posterior Adiposity Index: A Quantitative Selection Tool for Adrenalectomy Approach.

J Surg Res. 233: 26-31Chai Y.J. Yu H.W. Song R.Y. et al.

Lateral Transperitoneal Adrenalectomy Versus Posterior Retroperitoneoscopic Adrenalectomy for Benign Adrenal Gland Disease: Randomized Controlled Trial at a Single Tertiary Medical Center.

Ann Surg. 269: 842-848Barczyński M. Konturek A. Nowak W.

Randomized clinical trial of posterior retroperitoneoscopic adrenalectomy versus lateral transperitoneal laparoscopic adrenalectomy with a 5-year follow-up.

Ann Surg Nov. 260 (): 740-747Kozłowski T. Choromanska B. Wojskowicz P. et al.

Laparoscopic adrenalectomy: lateral transperitoneal versus posterior retroperitoneal approach - prospective randomized trial.

Wideochir Inne Tech Maloinwazyjne. 14: 160-169Ma W. Mao Y. Zhuo R. et al.

Surgical outcomes of a randomized controlled trial compared robotic versus laparoscopic adrenalectomy for pheochromocytoma.

Eur J Surg Oncol. 46: 1843-1847Margonis G.A. Kim Y. Prescott J.D. et al.

Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes.

Ann Surg Oncol. 23: 134-141Delozier O.M. Stiles Z.E. Deschner B.W. et al.

Implications of Conversion during Attempted Minimally Invasive Adrenalectomy for Adrenocortical Carcinoma.

Ann Surg Oncol. 28: 492-501Huynh K.T. Lee D.Y. Lau B.J. et al.

Impact of Laparoscopic Adrenalectomy on Overall Survival in Patients with Nonmetastatic Adrenocortical Carcinoma.

J Am Coll Surg. 223: 485-492Grubbs E.G. Callender G.G. Xing Y. et al.

Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane.

Ann Surg Oncol. 17: 263-270Fassnacht M. Dekkers O.M. Else T. et al.

European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.

Eur J Endocrinol. 179: G1-G46Wachtel H. Roses R.E. Kuo L.E. et al.

Adrenalectomy for Secondary Malignancy: Patients, Outcomes, and Indications.

Ann Surg. 274: 1073-1080Mittendorf E.A. Lim S.J. Schacherer C.W. et al.

Melanoma adrenal metastasis: natural history and surgical management.

Am J Surg Mar. 195 (): 363-368Vazquez B.J. Richards M.L. Lohse C.M. et al.

Adrenalectomy improves outcomes of selected patients with metastatic carcinoma.

World J Surg. 36: 1400-1405Vlk E. Ebbehoj A. Donskov F. et al.

Outcome and prognosis after adrenal metastasectomy: nationwide study.

BJS Open. : 6https://doi.org/10.1093/bjsopen/zrac047Russo A.E. Untch B.R. Kris M.G. et al.

Adrenal Metastasectomy in the Presence and Absence of Extraadrenal Metastatic Disease.

Ann Surg Aug. 270: 373-377Funder J.W. Carey R.M. Mantero F. et al.

The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.

J Clin Endocrinol Metab. 101: 1889-1916Clark 3rd, D. Ahmed M.I. Calhoun D.A.

Resistant hypertension and aldosterone: an update.

Can J Cardiol. 28: 318-325Dekkers T. Prejbisz A. Kool L.J.S. et al.

Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial.

Lancet Diabetes Endocrinol. 4: 739-746Lim V. Guo Q. Grant C.S. et al.

Accuracy of adrenal imaging and adrenal venous sampling in predicting surgical cure of primary aldosteronism.

J Clin Endocrinol Metab. 99: 2712-2719Zhu L. Zhang Y. Zhang H. et al.

Comparison between adrenal venous sampling and computed tomography in the diagnosis of primary aldosteronism and in the guidance of adrenalectomy.

Medicine (Baltimore). 95: e4986Umakoshi H. Ogasawara T. Takeda Y. et al.

Accuracy of adrenal computed tomography in predicting the unilateral subtype in young patients with hypokalaemia and elevation of aldosterone in primary aldosteronism.

Clin Endocrinol (Oxf). 88: 645-651Liu C. Lv Q. Chen X. et al.

Preoperative selective vs non-selective α-blockade in PPGL patients undergoing adrenalectomy.

Endocr Connect. 6: 830-838Buitenwerf E. Osinga T.E. Timmers H. et al.

Efficacy of α-Blockers on Hemodynamic Control during Pheochromocytoma Resection: A Randomized Controlled Trial.

J Clin Endocrinol Metab. 105: 2381-2391Kong H. Li N. Yang X.C. et al.

Nonselective Compared With Selective α-Blockade Is Associated With Less Intraoperative Hypertension in Patients With Pheochromocytomas and Paragangliomas: A Retrospective Cohort Study With Propensity Score Matching.

Anesth Analg. 132: 140-149Siddiqi H.K. Yang H.Y. Laird A.M. et al.

Utility of oral nicardipine and magnesium sulfate infusion during preparation and resection of pheochromocytomas.

Surgery. 152: 1027-1036Brunaud L. Boutami M. Nguyen-Thi P.L. et al.

Both preoperative alpha and calcium channel blockade impact intraoperative hemodynamic stability similarly in the management of pheochromocytoma.

Surgery. 156 (): 1410-1417Groeben H. Nottebaum B.J. Alesina P.F. et al.

Perioperative α-receptor blockade in phaeochromocytoma surgery: an observational case series.

Br J Anaesth Feb. 118: 182-189Roman-Gonzalez A. Zhou S. Ayala-Ramirez M. et al.

Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma.

Ann Surg. 268: 172-178Fishbein L. Del Rivero J. Else T. et al.

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma.

Pancreas. 50: 469-493Niemeijer N.D. Alblas G. van Hulsteijn L.T. et al.

Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis.

Clin Endocrinol (Oxf). 81: 642-651Pryma D.A. Chin B.B. Noto R.B. et al.

Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma.

J Nucl Med. 60: 623-630Severi S. Bongiovanni A. Ferrara M. et al.

Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials.

ESMO Open. 6: 100171Jimenez C. Subbiah V. Stephen B. et al.

Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas.

Cancers (Basel). : 12https://doi.org/10.3390/cancers12082307Fishbein L. Ben-Maimon S. Keefe S. et al.

SDHB muta